2022
COVID-19 Traumatic Disaster Appraisal and Stress Symptoms Among Health Care Workers
Olson K, Fogelman N, Maturo L, Alvarado J, Ball S, Forray A, Hu M, Ivy M, Kapo J, Krystal J, Mayes L, Rohrbaugh R, Southwick S, Tebes J, Wassel B, Sinha R. COVID-19 Traumatic Disaster Appraisal and Stress Symptoms Among Health Care Workers. Journal Of Occupational And Environmental Medicine 2022, 64: 934-941. PMID: 35959912, PMCID: PMC9640251, DOI: 10.1097/jom.0000000000002673.Peer-Reviewed Original ResearchConceptsHealth care workersCare workersChronic mental healthCross-sectional evaluationTotal Worker HealthAdverse psychological outcomesPredictive factorsSevere stress eventsResponse rateCare qualityMental healthAdverse effectsPrivate practitionersHigh levelsWorkers' healthSense of controlStress symptomsPsychological outcomesLevel of educationGreater proportionHealthPandemicStress eventsSymptomsWorkers
2019
Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment
Quagliato LA, Cosci F, Shader RI, Silberman EK, Starcevic V, Balon R, Dubovsky SL, Salzman C, Krystal JH, Weintraub SJ, Freire RC, Nardi AE, Benzodiazepines I. Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment. Journal Of Psychopharmacology 2019, 33: 1340-1351. PMID: 31304840, DOI: 10.1177/0269881119859372.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsMore adverse effectsPD treatmentPanic disorderReuptake inhibitorsRisk factorsClinical trialsAdverse effectsCochrane Central RegisterAdverse event ratesCommon side effectsShort-term treatmentClass of drugsWeb of ScienceAbnormal ejaculationLibido reductionDry mouthAdverse eventsCentral RegisterPharmacologic treatmentSSRI treatmentAcute treatmentControlled TrialsPrimary outcome
2015
Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants
Abdallah CG, Averill LA, Krystal JH. Ketamine as a promising prototype for a new generation of rapid‐acting antidepressants. Annals Of The New York Academy Of Sciences 2015, 1344: 66-77. PMID: 25727103, PMCID: PMC4412785, DOI: 10.1111/nyas.12718.Peer-Reviewed Original ResearchConceptsOpen-label studyRobust antidepressant effectsRapid-acting antidepressantsNeurobiology of depressionRoute of administrationModerate adverse effectsMechanism of actionTrauma-related disordersTraditional antidepressantsAntidepressant effectsTransient mildChronic treatmentControlled TrialsClinical effectsOptimal dosingPsychopharmacologic interventionsPatient groupPatient populationTreatment targetsKetamineAntidepressantsRelevant biomarkersAdverse effectsNeurobiological underpinningsInfusion
2001
NMDA receptor regulation of memory and behavior in humans
Newcomer J, Krystal J. NMDA receptor regulation of memory and behavior in humans. Hippocampus 2001, 11: 529-542. PMID: 11732706, DOI: 10.1002/hipo.1069.Peer-Reviewed Original ResearchConceptsNMDA receptor hypofunctionReceptor hypofunctionN-methyl-D-aspartate (NMDA) receptor hypofunctionNMDA receptor antagonist drugsNMDA receptor systemAge-related decreaseNMDA receptor regulationReceptor antagonist drugsClinical syndromeNeuropathological featuresNMDA antagonistsNMDA receptorsNeurotoxic processesAntagonist drugsAdult brainHypofunctionBehavioral dysfunctionHuman studiesRange of effectsReceptor regulationReceptor systemBrain functionBrain ageAdverse effectsDisease conditions
1997
Benzodiazepine Receptor Antagonists
Abi-Dargham A, Charney D, Krystal J. Benzodiazepine Receptor Antagonists. CNS Drugs 1997, 8: 244-256. DOI: 10.2165/00023210-199708030-00007.Peer-Reviewed Original ResearchBenzodiazepine receptorsIdiopathic recurrent stuporBenzodiazepine receptor antagonistPotential therapeutic benefitBenzodiazepine toleranceCerebral ischaemiaGABAergic systemΓ-aminobutyric acidReceptor antagonistMovement disordersNeuronal markersSleep disordersTherapeutic benefitCognitive disordersPotential treatmentNeuropsychiatric illnessOnly agentInverse agonistFlumazenilPharmacological investigationsAdverse effectsReceptorsDisordersImaging agentEpilepsy